NCT06297408View on ClinicalTrials.gov

Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2026

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Relma-cel

CD19-targeted Chimeric AntigenReceptor (CAR) T Cells

All Listed Sponsors

lead

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY